Solid Biosciences (SLDB) Assets Average (2018 - 2026)

Solid Biosciences (SLDB) has 9 years of Assets Average data on file, last reported at $327.7 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average rose 23.07% year-over-year to $327.7 million; the trailing twelve-month figure through Mar 2026 stood at $327.7 million (up 23.07% YoY), and the FY2025 full-year result was $210.6 million, up 19.12% from the prior year.
• Assets Average grew to $327.7 million in Q1 2026, from $253.2 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $327.7 million in Q1 2026 to a low of $174.8 million in Q4 2023.
• A 5-year average of $236.0 million and a median of $221.4 million in 2024 frame the typical range for Assets Average.
• Across the five-year window, Assets Average dropped 24.51% in 2022 and jumped 35.97% in 2025, its largest moves.
• Tracing SLDB's Assets Average over 5 years: stood at $222.4 million in 2022, then decreased by 21.37% to $174.8 million in 2023, then increased by 14.53% to $200.2 million in 2024, then rose by 26.46% to $253.2 million in 2025, then grew by 29.42% to $327.7 million in 2026.
• Business Quant data shows SLDB's Assets Average at $327.7 million in Q1 2026, $253.2 million in Q4 2025, and $291.1 million in Q3 2025.